Safety assessment of chronic oral exposure to iron oxide nanoparticles.
Iron oxide nanoparticles with engineered physical and biochemical properties are finding a rapidly increasing number of biomedical applications. However, a wide variety of safety concerns, especially those related to oral exposure, still need to be addressed for iron oxide nanoparticles in order to reach clinical practice. Here, we report on the effects of chronic oral exposure to low doses of γ-Fe2O3 nanoparticles in growing chickens. Animal observation, weight, and diet intake reveal no adverse signs, symptoms, or mortality. No nanoparticle accumulation was observed in liver, spleen, and duodenum, with feces as the main excretion route. Liver iron level and duodenal villi morphology reflect the bioavailability of the iron released from the partial transformation of γ-Fe2O3 nanoparticles in the acid gastric environment. Duodenal gene expression studies related to the absorption of iron from γ-Fe2O3 nanoparticles indicate the enhancement of a ferric over ferrous pathway supporting the role of mucins. Our findings reveal that oral administration of iron oxide nanoparticles is a safe route for drug delivery at low nanoparticle doses.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición, ICTAN-CSIC, Ciudad Universitaria, José Antonio Novais, 10, 28040 Madrid, Spain.
Susana
S
Chamorro
Lucía
L
Gutiérrez
María Pilar
MP
Vaquero
Dolores
D
Verdoy
Gorka
G
Salas
Yurena
Y
Luengo
Agustín
A
Brenes
Francisco
F
José Teran
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002645:Chickens; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004435:Eating / Q000187:drug effects; D005290:Ferric Compounds / Q000378:metabolism / Q000493:pharmacokinetics / Q000633:toxicity*; D015870:Gene Expression / Q000187:drug effects; D007501:Iron / Q000378:metabolism; D053768:Metal Nanoparticles / Q000633:toxicity*
D005290:Ferric Compounds; C000499:ferric oxide; D007501:Iron